Clinical TrialAug 11, 2026, 08:31 AM
Cingulate Publishes CTx-1301 Bioavailability Data for ADHD Drug
AI Summary
Cingulate Inc. announced the publication of a peer-reviewed manuscript in CNS Drugs, detailing the comparative bioavailability of CTx-1301, its lead ADHD product candidate. The study demonstrated CTx-1301's trimodal release profile, providing rapid onset and sustained medication exposure throughout the active day, with fewer adverse events than the reference bimodal formulation. This publication, following the Phase 3 efficacy study, establishes a strong scientific foundation for CTx-1301's clinical performance and proprietary drug delivery.
Key Highlights
- Publication in CNS Drugs details CTx-1301's comparative bioavailability.
- Study showed rapid early exposure for potential fast onset of action.
- Achieved statistically significant higher plasma concentrations later in day.
- Designed for controlled decline in drug concentrations to reduce "wear-off."
- Demonstrated fewer treatment-emergent adverse events than reference product.
- CTx-1301 is a once-daily, multi-core tablet for ADHD treatment.
Price Impact
More from CING